With what are being called “impressive” results for its blood cancer treatment, the small biotech featured in today’s article is rivaling first-in-class treatments from the likes of Gilead Sciences and Novartis. For more on this biotech, its donor cell-derived cancer treatment, and the bullish case for the stock, CLICK HERE.
With Its “Impressive” Blood Cancer Treatment, This Small Biotech Is Rivaling Gilead And Novartis
